Survival by cytogenetic (CG) category and other prognostic factors in patients tested at diagnosis. (A) In patients without unfavorable cytogenetics, the Lille score failed to differentiate between intermediate-risk (Lille 1) and high-risk (Lille 2) patients. (B) Using the factors identified as being independently significant on the multivariate model (hemoglobin < 10 g/dL or transfusion dependency, platelets < 100 × 109/L, performance status ≥ 1), patients without unfavorable cytogenetics were effectively divided into risk categories with median survivals of 69, 57, 29, and 16 months, respectively (for 0, 1, 2, and 3 factors, P < .001). Patients with unfavorable or very unfavorable karyotypes had a dismal survival (median, 6 months) irrespective of the number of factors present.
